124041-03-8

Basic information

• Product Name: Pyrimidine, 4-chloro-6-(4-nitrophenoxy)-
• CAS NO: 124041-03-8
• Molecular Formula: C10H6ClN3O3
• Molecular Weight: 251.629
• Mol File: 124041-03-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Pyrimidine, 4-chloro-6-(4-nitrophenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 4-chloro-6-(4-nitrophenoxy)-(124041-03-8)
• EPA Substance Registry System: Pyrimidine, 4-chloro-6-(4-nitrophenoxy)-(124041-03-8)

Safety Data

• Hazardous Substances Data: 124041-03-8(Hazardous Substances Data)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 100-02-7 4-nitro-phenol 
• 1193-21-1 4,6-dichloropyrimidine 

Downstream Products

• 1229607-83-3 tert-butyl 6-(4-nitrophenoxy)pyrimidin-4-ylcarbamate 
• 417724-32-4 N-(4-(6-Chloropyrimidin-4-yloxy)phenyl)-N'-phenylurea 

Relevant articles and documents

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity against VEGFR2, p38α, and B-Raf

A series of diarylurea inhibitors of the cardiac-specific kinase TNNI3K were developed to elucidate the biological function of TNNI3K and evaluate TNNI3K as a therapeutic target for the treatment of cardiovascular diseases. Utilizing a structure-based design, enhancements in kinase selectivity were engineered into the series, capitalizing on the established X-ray crystal structures of TNNI3K, VEGFR2, p38α, and B-Raf. Our efforts culminated in the discovery of an in vivo tool compound 47 (GSK329), which exhibited desirable TNNI3K potency and rat pharmacokinetic properties as well as promising kinase selectivity against VEGFR2 (40-fold), p38α (80-fold), and B-Raf (>200-fold). Compound 47 demonstrated positive cardioprotective outcomes in a mouse model of ischemia/reperfusion cardiac injury, indicating that optimized exemplars from this series, such as 47, are favorable leads for discovering novel medicines for cardiac diseases.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

New aminopyrimidine derivatives as inhibitors of the TAM family

In this study, we describe the synthesis of new pyrimidine analogs of BMS-777607, a potent and selective inhibitor of Met kinase. Inhibition of Met and Axl remained high whereas inhibition of Tyro3 and Mer decreased to some extend. The preferential modera